Lidokain Sad

Lidocaine Hydrochloride, the active ingredient in Lidokain Sad, is a local anesthetic presented as an intravenous solution for use in clinical settings. It is employed to provide local anesthesia and to manage certain cardiac arrhythmias, particularly ventricular arrhythmias, in adult patients under professional supervision.

GNH USA supplies Lidokain Sad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is used in medical practice to achieve rapid nerve block and to stabilize cardiac rhythm in specific arrhythmic conditions.

- Local anesthesia: provides temporary loss of sensation for minor surgical or diagnostic procedures. - Ventricular arrhythmias: helps suppress abnormal rapid heart rhythms originating in the ventricles. - Emergency cardiac care: used intravenously to control acute arrhythmic episodes during resuscitation.

Adverse reactions may occur with intravenous lidocaine administration. Monitoring for both common and serious events is recommended.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Nausea: mild gastrointestinal upset. - Metallic taste: temporary alteration of taste perception. - Tingling or numbness: localized sensory changes. - Hypotension: mild drop in blood pressure.

Serious or Rare Side Effects: - Seizures: uncontrolled convulsive activity. - Cardiac arrest: severe disruption of heart rhythm. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty. - Methemoglobinemia: reduced oxygen‑carrying capacity of blood. - Respiratory depression: slowed or shallow breathing.

Before administering Lidokain Sad, clinicians should consider several safety measures. - Cardiac monitoring: observe heart rhythm continuously during intravenous infusion. - Liver function: assess hepatic impairment as lidocaine is metabolized hepatically. - Drug allergies: verify no known hypersensitivity to amide‑type local anesthetics. - Dosage adjustment: modify dose in patients with severe cardiac or hepatic disease. - Store at ambient temperature: keep below 25 °C, protect from moisture and light, and retain in original packaging.

Lidocaine may interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): can increase lidocaine plasma levels and toxicity. - Amiodarone: potent inhibitor of hepatic metabolism, raising lidocaine concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., cimetidine, erythromycin): may modestly elevate lidocaine levels. - Beta‑blockers (e.g., propranolol): can enhance bradycardic effects. - Diuretics (e.g., furosemide): may affect electrolyte balance, influencing cardiac response.